Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Two of oncology's most-used immunotherapy drugs go head-to-head — and it's essentially a tie. A large US Veterans Affairs study found that pembrolizumab and nivolumab deliver nearly identical effectiveness and safety as first-line treatments for advanced or metastatic melanoma. With no clear clinical winner, experts say the choice should come down to cost, logistics, and patient preference.
When it comes to treating advanced melanoma, pembrolizumab and nivolumab — two of the most widely used PD-1 inhibitors in oncology — appear to be clinical equals. A large real-world study published in JAMA Network Open analyzed outcomes in 742 patients with advanced, unresectable, or metastatic melanoma treated within the US Veterans Affairs health system, finding no meaningful differences between the two drugs across key endpoints.
Despite the widespread use of both agents, a head-to-head randomized trial had never been conducted — making this the most comprehensive comparative data available to date. Researchers used propensity score adjustment to account for differences between patient groups and followed patients for over five years.
Why it matters: With no clinical edge for either drug, the decision of which to prescribe should be driven by financial, operational, and logistical factors — a meaningful shift that could influence formulary decisions and reduce costs for patients and health systems alike.
